Verily closes acquisition of clinical research software firm SignalPath

September 1, 2021 (Last Updated September 1st, 2021 14:38)

Nearly 100 SignalPath employees will become part of Verily’s clinical research business.

Verily closes acquisition of clinical research software firm SignalPath
The companies will work together to bring drugs more quickly to patients. Credit: Michal Jarmoluk from Pixabay.

Alphabet unit Verily has closed the acquisition of a clinical research software developer SignalPath, boosting its clinical research capabilities.

SignalPath co-founder and CEO Brad Hirsch and his management team will continue with the company.

The company will stay in its current location in North Carolina, US, expanding Verily’s presence in the state.

Meanwhile, nearly 100 employees at SignalPath will become part of Verily’s clinical research business.

Verily Clinical Studies Platforms president Amy Abernethy said: “Joining forces helps us to accelerate our shared ambition to make clinical research work better for everyone involved, and get medicines and devices to patients more quickly.

“Together, we’ll bring more comprehensive and digital solutions to the clinical trial ecosystem and modernise the way clinical research is conducted.”

SignalPath designed a clinical trial management system (CTMS), which provides software for trial sites to enhance the ease, quality and efficacy of carrying out clinical research.

The deal will bolster Verily’s current clinical trial system and evidence generation platform called Baseline.

Baseline facilitates improved and quicker trial implementation, enhanced data collection and analysis, as well as flexible options for decentralised and hybrid trials.

It also allows the capture of real-world data, including data from new sensors and biomarkers.

Verily added that the Baseline is developed to involve patients and clinicians in research.

The platform is additionally intended to allow easy and quick trials while gathering quality, extensive data for all clinical research types such as site-based trials, decentralised trials and real-wide studies.

In a separate development, ConcertAI has agreed to enable digital clinical trials for the Quality Cancer Care Alliance Network (QCCA).

Under the partnership, ConcertAI’s Digital Trial Solution will be incorporated into QCCA’s network, which comprises 18 community-based oncology practices.

QCCA will now have access to several trials from biopharma sponsors, tools for quick participant identification and enrolment, clinical research software and solutions to conduct digital trials.